Epidemiology of drug resistance:
The case of *Staphylococcus aureus*
and coagulase-negative staphylococci infections

Ernesto Calderón-Jaimes, MC, MSP,[(1)] Luz E Espinosa de los Monteros, Dra en C,[(1)]
Renata Avila-Beltrán, MC.[(1)]

Abstract

Objective. To study the activity of several antibiotics against *Staphylococcus* spp. *Material and Methods.* The study included 1209 strains of *Staphylococcus* spp. from two institutions; Instituto Nacional de Pediatría (National Institute of Pediatrics) and Hospital Infantil de México Federico Gómez (Mexico City Children's Hospital). Minimum Inhibitory Concentrations of all antibiotics were determined by the agar macrodilution technique and standard methods from the National Committee for Clinical Laboratory Standards. *Results.* Resistance of *S. aureus* was 14.2% and that of coagulase-negative staphylococci was 53.4%. The activity of different antibiotics is presented in detail. *Conclusions.* Surveillance of strains resistant to methicillin is necessary. The English version of this paper is available too at: http://www.insp.mx/salud/index.html

Resumen

Objetivo. Determinar la frecuencia de la resistencia a la meticilina y la actividad de varios antibióticos. *Material y métodos.* Se incluyeron 1 209 cepas de *Staphylococcus* spp. procedentes de pacientes del Instituto Nacional de Pediatría y del Hospital Infantil de México Federico Gómez. Se utilizó la técnica de dilución en placas con agar. El procedimiento e interpretación fueron acordes con lo establecido por el National Committee for Clinical Laboratory Standards. *Resultados.* La frecuencia de la resistencia de *S. aureus* fue de 14.2% y de 53.4% en los *Staphylococcus* coagulasa negativa. La actividad de otros antimicrobianos se presenta en el texto. *Conclusiones.* Es necesario vigilar continuamente la progresión de la resistencia de *Staphylococcus* spp. a la meticilina.El texto completo en inglés de este artículo también está disponible en: http://www.insp.mx/salud/index.html

(1)   Departamentos de Bacteriología Intestinal, Inmunoquímica y Biología Celular. Hospital Infantil de México "Federico Gómez". México, D.F., México.

Staphylococcus aureus remains a versatile and dangerous pathogen in humans, since it is one of the most common causes of nosocomial and community-acquired infection. SA infections are often acute and pyogenic, and if untreated, may spread to surrounding tissue or via bacteremia to metastatic sites.[1-3]

Some of the most common infections caused by SA involve the skin, including furuncles, cellulitis, impetigo, and postoperative wound infections of various sites. Some of the most serious infections produced by SA are bacteremia, pneumonia, osteomyelitis, endocarditis, scalded skin syndrome, empyema, toxic shock syndrome, and abscesses of the muscle and various intra-abdominal organs.[4-8]

The role of coagulase-negative staphylococci in causing nosocomial infections has been recognized and well documented over the last two decades, specially for the species *S. epidermidis.* The infection rate has been correlated with the increase in the use of prosthetic and indwelling devices and the growing number of immunocompromised patients in hospitals. Nosocomial infections have been a mayor cause of morbidity and mortality.[9-12]

Methicillin-resistant staphylococci have become a serious problem in many parts of the world. Although the incidence of methicillin-resistant strains of staphylococci varies from country to country and from hospital to hospital, it has been steadily increasing worldwide in the last decade.[13-16]

The present work was carried out to study the activity of several antimicrobials against *S. aureus* and coagulase negative staphylococci strains recovered from patients with severe infections.

Material and Methods

This study included 296 *Staphylococcus* strains (84 *S. aureus* and 212 coagulase-negative staphylococci strains) collected in patients from the National Institute of Pediatrics during 1998-1999, and 913 *Staphylococcus* strains (127 *S. aureus* and 786 coagulase-negative staphylococci strains) collected in patients from Hospital Infantil de México Federico Gómez during 1998-2000; both of these hospitals are tertiary care referral centers. Data for each strain was obtained from the Institutional Surveillance System for Antimicrobial Resistance, to monitor the frequency of occurrence and antimicrobial susceptibility of both nosocomial and community-acquired bacterial pathogens.

The organisms were recovered from a variety of clinical specimens, including normally sterile body fluids (71 in blood; 165 in CSF, mainly from ventriculitis; 53 in pleural fluid; 22 in peritonitis; 7 in joint fluid; 265

in abscesses; 65 in urine cultures; 36 in dialysis, and 525 in prosthetic and indwelling devices, mainly catheters). Only one isolate from each clinical episode was included in the analyses. Isolates (coagulase-negative staphylococci) were judged to be clinically significant by two criteria: a) isolation of strain in pure culture from the infected site or body fluid, b) repeated isolation of the same strain over the course of the infection. *Staphylococcus* strains were kept frozen at -70 °C until testing.[17]

Antimicrobials used in this study were oxacillin, amoxicillin-clavulanate, ticarcillin-clavulanate, cefepime, ceftriaxone, imipenem, clarithromycin, gentamicin, amikacin, ciprofloxacin, teicoplanin, vancomicyn, and linezolid. The agents were supplied as laboratory powders of known potency, and stock solutions were made as recommended by the manufacturers.

Prior to being tested, each isolate was subcultured at least twice on mannitol and NaCl agar plates (BBL, Mexico) to ensure purity and optimal characteristics. Minimum Inhibitory Concentrations (MIC) of all of antibiotics tested were determined by use of a broth macrodilution technique and standard methods defined by the National Committee for Clinical Laboratory Standards (NCCLS).[18,19] Mueller-Hinton broth was used as the growth medium throughout the study (BBL, Mexico). The final bacterial inoculum concentration used was 5×10^5 cfu/mL. Trays were incubated 24 h at 35 °C in ambient air before determination of MIC values. National Committee for Clinical Laboratory Standards breakpoints were used to interpret MIC data. Appropriate quality control was performed by use of *Staphylococcus aureus* ATCC 29213 (oxacillin susceptible). Linezolid is an investigational drug; no susceptibility breakpoints are available for it. The manufacturer defined ≤4 µg/mL as susceptible and ≥ 4 µg/mL as resistant.

The current NCCLS breakpoint for oxacillin susceptibility for *Staphylococcus* was MIC ≤2 µg/mL for susceptible strains and MIC ≥4 µg/mL for resistant strains. All isolates were screened for methicillin resistance on Mueller-Hinton agar added with NaCl (2%). Colonies that grew only on oxacillin-free plates and were both mannitol and coagulase-positive, were considered methicillin susceptible *Staphylococcus aureus* (MSSA) Coagulase-positive organisms that also grew on mannitol salt plates with oxacillin were identified as methicillin resistant *Staphylococcus aureus.* Coagulase-negative staphylococci were also probed and considered in accordance as coagulase-negative methicillin susceptible or coagulase-negative methicillin resistant.

Results

Susceptibility to oxacillin differed significantly among staphylococci, with 14.2% of *S. aureus* isolates and 53.4% of coagulase-negative staphylococci isolates showing resistance to oxacillin, and therefore were cross-resistant to all other β-lactam compounds. Oxacillin-dicloxacillin, and also other useful antistaphylococcal compounds, were predictably highly active against oxacillin-susceptible isolates.

Regarding non-β-lactam antibiotics, all staphylococci remained fully susceptible to the glycopeptide antibiotics vancomycin and teicoplanin (MIC$_{90}$ ≤2 µg/mL). Linezolid, a new class of antimicrobial agent that inhibits bacterial protein synthesis by blocking formation of the initiation complex, demonstrated 100% activity against all *Staphylococcus* in this *in vitro* study.

Few oxacillin-resistant staphylococci were susceptible to ciprofloxacin, whereas 81% of the oxacillin-susceptible *S. aureus* were susceptible to amikacin. A total of 94.4% of the coagulase-negative oxacillin-susceptible strains were also susceptible to that aminoglycoside. Reduced susceptibility to all other drugs tested was higher among methicillin-resistant than among methicillin-susceptible isolates, especially susceptibility to clarithromycin and gentamicin.

The activity of different antibiotics against *S. aureus* and coagulase-negative staphylococci is shown in tables I and II.

Discussion

The development of antimicrobial resistance nearly always has followed the therapeutic use of antimicrobial agents. When penicillin was introduced for clinical use, virtually all strains of *S. aureus* were susceptible. Unfortunately, within less than a decade, serious resistance problems were seen in many major medical centers. *S. aureus* acquired β-lactamase genes, rendering the organism penicillin-resistant. To combat this problem, researchers developed extended-spectrum penicillins and cephalosporins. These new antimicrobials succeeded only partially in overcoming the problem of resistance. Methicillin-resistant strains of staphylococci have been known since the early 1960s. Recently, strains relatively resistant to glycopeptides have been described (MIC ≤8 µg/mL).[15] Treatment of *Staphylococcus* infections has become more difficult because of multidrug-resistant strains.

Staphylococcus aureus and coagulase-negative staphylococci have been identified by the National Nosocomial Infections Surveillance system as the leading overall causes of hospital acquired infections.[5,15,20]

The percentage of methicillin-resistant *S. aureus* (MRSA) in hospitals in the United States rose from 2.4% in 1975 to 29 % in 1991, with a methicillin-resistant *Staphylococcus aureus* rate of 38% at large hospitals.[3] The highest resistance rates occurred among isolates from patients in intensive care units,

Table I

ACTIVITY (µG/ML) SPECTRUM OF VARIOUS ANTIMICROBIAL AGENTS AGAINST 211 STRAINS OF STAPHYLOCOCCUS AUREUS. MEXICO, D.F., MEXICO, 1998-1999

Drugs	Methicillin-susceptible Staphylococcus aureus *(n=181)*		Susceptible %	Methicillin-resistant Staphylococcus aureus *(n=30)*		Susceptible %
	Minimum inhibitory concentration$_{50}$	*Minimum inhibitory concentration$_{90}$*		*Minimum inhibitory concentration$_{50}$*	*Minimum inhibitory concentration$_{90}$*	
Oxacillin	<0.5	<2	94.4	>16	>16	0
Amoxacillin-clavulanate	1	2	94.0	>16	>16	0
Ticarcillin-clavulanate	1	4	92.8	>16	>16	0
Cefepime	2	4	97.2	>16	>16	0
Ceftriaxone	2	4	95.0	>16	>16	0
Imipenem	0.12	0.25	97.2	>8	>8	0
Clarithromycin	0.5	>8	76.2	>8	>8	10
Gentamicin	0.5	2	92.8	>16	>16	16.6
Amikacin	0.5	1	94.4	>8	>8	16.6
Ciprofloxacin	0.25	2	88.3	>2	>2	10
Teicoplanin	0.5	1	100.0	1	2	96.6
Vancomycin	1	1	100.0	1	2	100
Linezolid*	<0.25	2	100.0	1	2	100

* Investigational drug. No susceptibility breakpoints are available in NCCLS[18,19]

Table II
ACTIVITY (µG/ML) SPECTRUM OF VARIOUS ANTIMICROBIAL AGENTS AGAINST 998 STRAINS
OF COAGULASE-NEGATIVE STAPHYLOCOCCI. MEXICO, D.F., MEXICO, 1998-1999

Drugs	Methicillin susceptible coagulase-negative staphylococci (n=465)		Susceptible	Methicillin-resistant coagulase-negative staphylococci (n=533)		Susceptible
	Minimum inhibitory concentration$_{50}$	Minimum inhibitory concentration$_{90}$	%	Minimum inhibitory concentration$_{50}$	Minimum inhibitor concentration$_{90}$	%
Oxacillin	<1	<2	98.9	4	>16	0
Amoxicillin-clavulanate	0.5	2	97	8	>16	0
Ticarcillin-clavulanate	0.25	2	97	4	>16	0
Cefepime	1	4	98.9	8	>16	0
Ceftriaxone	1	8	91.8	16	>16	0
Imipenem	0.12	0.25	98.9	1	>8	0
Clarithromycin	0.5	>8	40.7	>8	>16	18.2
Gentamicin	0.12	16	81	8	>16	28.3
Amikacin	0.12	16	81	8	>8	28.3
Ciprofloxacin	0.12	>2	43	4	>4	43
Teicoplanin	1	2	100	1	4	100
Vancomycin	0.5	2	100	1	2	100
Linezolid*	0.25	2	100	0.5	2	100

* Investigational drug. No susceptibility breakpoints are available in NCCLS[18,19]

followed in decreasing order by rates among isolates from outpatients. These organisms included methicillin-resistant coagulase-negative staphylococci in intensive care units (75%), non-ICUs (60.4%) and outpatient areas (44.5%); and MRSA in intensive care units (35.2%), non-intensive care units (31.9%) and outpatients areas (17.7%).[21]

S. aureus and coagulase-negative staphylococci are virulent pathogens that are currently the most common cause of infections in hospitalized patients. Increasing resistance to antibiotics indicates that their prevalence will continue to rise.

Given the number and severity of staphylococcal infections, it is important to understand the nature and pathogenesis of infections and the current strategies available for therapy and prevention.

The core resistance phenotype that seems to be mostly associated with the persistence of *S. aureus* in the hospital is methicillin resistance. This resistance is due to the acquisition of a new penicillin-binding protein, PBP2a.[14] This protein has low affinity for most β-lactam antibiotics, and therefore, mediates cross-resistance to all these compounds.[3,14]

Methicillin resistance in nosocomial isolates of *S. aureus* and coagulase-negative staphylococci has been dramatically increasing, and is also associated with resistance to other useful antistaphylococcal compounds.[15,20]

This high level of resistance not only impedes successful therapy for infections but also allows the organism to persist in the hospital, expanding its reservoir. Study results suggest that the current levels of methicillin-resistance in *S. aureus* and CNS have a similar pattern to what has already been established.[15]

Although the incidence of- methicillin resistant *S. aureus* and methicillin-resistant *Staphylococcus epidermidis* strains and other methicillin resistant staphylococci varies from hospital to hospital, it has been increasing and often exceeds 50%, as is in the case of coagulase-negative methicillin resistant staphylococci, which is a major cause of medical device-associated infections, specially in immunocompromised patients, and the excessive use of vancomycin in the empirical treatment is complicated by the emergence of multiresistant strains.[15]

A semisynthetic penicillin (dicloxacillin) would be the drug of choice for b-lactamase-producing strains, as well as in the case of *S. aureus* and methicillin-susceptible coagulase-negative staphylococci. Cephalotin and clindamycin are acceptable alternatives. Vancomycin should be reserved to treat methicillin-resistant proved cases. The extensive use of vancomycin may help promote colonization and infections with vancomycin enterococci.

Today, chemotherapy for *Staphylococcus* methicillin-resistant infections is becoming increasingly dif-

ficult. With the increasing frequency of nosocomial and device-related infections associated with methicillin-resistant *staphyloccocus epidermidis*, and the failure of glycopeptide antibiotic therapy in those infections, the pharmaceutical industry is searching and responding with alternative agents, such as a combination drug consisting of semisynthetic derivatives of streptogramin A (dalfopristin) and streptogramin B (quinupristin) (Synercid), used in Europe for several years with no significant increase in resistance over time.[22]

The oxazolidinone antibiotics (PNU-1000766 and PNU-100592, Linezolid and Eperezolid), are other novel antimicrobial agents that have been shown to be active against most medically important gram-positive bacteria. In our study, the *in vitro* activity of Linezolid against *Staphylococcus*, either methicillin susceptible or resistant, was comparable with those of vancomycin.[23]

Since antibiotic use became widespread 50 years ago, bacteria have steadily and routinely developed resistance. Control of the emergence of resistance will depend on new approaches to prudent antibiotic use in hospitals and clinics, based in part on improved surveillance for methicillin-resistance staphylococci by currently available methods and on better systems to encourage staff adherence to follow isolation procedures.*

Acknowledgements

References

1. Lowy FD. *Staphylococcus aureus* infection. N Engl J Med 1998;320: 520-532.

2. Crossley KB, Archer GL, ed. The staphylococci in human diseases. Nueva York: Churchill Livingstone, 1997.

3. Archer GL. *Staphylococcus aureus*: A well-armed pathogen. Clin Infect Dis 1998;26:1179-1181.

4. Conterno LO, Wey SB, Castelo A. Risk factors for mortality in *Staphylococcus aureus* bacteremia. Infect Control Hosp Epidemiol 1998;19:32-37.

5. Romero-Vivas J, Rubio M, Fernández C, Picazo JJ. Mortality associated with nosocomial bacteremia due to methicillin-resistant *Staphylococcus aureus*. Clin Infect Dis 1995;21:1417-1423.

6. Musher OM, Lamm N, Daroniche RO, Young EJ, Hamill RJ, Landon GC. The current spectrum of *Staphylococcus aureus* infection in a tertiary care hospital. Medicine (Baltimore) 1994;73:186-208.

7. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994;154:26-34.

8. Witte W. Antibiotic resistance in gram-positive bacteria: Epidemiologic aspects. J Antimicrob Chemother 1999;44 (Suppl A): 1-9.

9. Kloos WE, Bannerman TL. Update on clinical significance of coagulase-negative staphylococci. Clin Microbial Rev 1994;7:117-140.

10. Viagappan N, Kelsey MC. The origin of coagulase-negative staphylococci isolated from blood cultures. J Hosp Infect 1995;30:217-223.

11. Raad L, Alrahwan A, Rolston K. *Staphylococcus epidermidis*: Emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26:1182-1187.

12. Rupp ME, Archer GL. Coagulase-negative staphylococci: Pathogens associated with medical progress. Clin Infect Dis 1994;19:231-243.

13. Waldvogel FA. New resistance in *Staphylococcus aureus*. N Engl J Med 1999;340:556-557.

14. Chambers HF. Methicillin resistance in staphylococci. Molecular and biochemical basis and clinical implications. Clin Microbiol Rev 1997;10: 781-791.

15. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML *et al*. Survey of bloodstream infections due to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America for the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 1999;33:283-297.

16. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl Med 1987;316: 927-931.

17. Kloos WK, Bannerman TL. *Staphylococcus* and *Micrococcus*. En: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, ed. Manual of clinical microbiology. 7th ed. Washington, D.C.: ASM Press, 1999: 264-282.

18. National Committee for Clinical Laboratory Standards. Antimicrobial susceptibility test for bacteria that grow aerobically: Approved Standard. 5th ed. Wayne (PA): National Committee for Clinical Laboratory Standards, 2000; NCCLS document M7-A5.

19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Tenth informational supplement Wayne (PA): National Committee for Clinical Laboratory Standards. 2000; M100-S10.

20. Emory TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6: 428-442.

21. Fridkin SK, Steward CD, Edwards JR, Pryor EE, Mc Gowan JE, Archivald LK *et al*. Surveillance of antimicrobial use and antimicrobial resistance in the United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999; 29: 245-252.

22. Brumfitt W, Hamilton-Miller JM, Shah S. *In vitro* activity of RP59500 a new semisynthetic antibiotic, against gram-positive bacteria. J Antimicrob Chemother 1992; 30 (Suppl A):27-37.

23. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM *et al*. Randomized comparison of Linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-4813.